Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland

Recommendations on the use of anticoagulants for the treatment of patients with heparin-induced thrombocytopenia in Switzerland

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug effect that occurs in 0.1–5% of heparin treated patients. Management of acute HIT currently involves (1) cessation of heparin exposure, and (2) inhibition of coagulation with an anticoagulant other than heparin. Several anti...

Full description

Bibliographic Details
Main Authors: Lorenzo A. Alberio, Anne Angelillo-Scherrer, Lars M. Asmis, Alessandro Casini, Pierre Fontana, Lukas Graf, Inga Hegemann, Johanna A. Kremer Hovinga, Wolfgang Korte, Thomas Lecompte, Martina Martinez, Michael Nagler, Jan-Dirk Studt, Dimitrios A. Tsakiris, Walter A. Wuillemin, members of the Working Party Hemostasis (WPH) of the Swiss Society of Hematology (SGH-SSH), in alphabetical order
Format: Article
Language:English
Published: SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2020-04-01
Series:Swiss Medical Weekly
Subjects:
anticoagulation
argatroban
bivalirudin
danaparoid
fondaparinux
Heparin
Online Access:https://www.smw.ch/index.php/smw/article/view/2776

Internet

https://www.smw.ch/index.php/smw/article/view/2776

Similar Items